UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 349

Sortiert nach

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Annals of oncology, 2021-08, Vol.32 (8), p.1005-1014

2021

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The New England journal of medicine, 2019-02, Vol.380 (7), p.617-628

2019

Link zum Volltext

Verfügbarkeit prüfen

The duration of fibre-optic intubation is increased by cricoid pressure. A randomised double-blind study

Acta anaesthesiologica Scandinavica, 2013-03, Vol.57 (3), p.358-363

2013

Link zum Volltext

Verfügbarkeit prüfen

The importance of the lumpectomy surgical margin status in long term results of breast conservation

Cancer, 1995-07, Vol.76 (2), p.259-267

1995

Link zum Volltext

Verfügbarkeit prüfen

Breast electron boost planning: comparison of CT and US

Radiology, 2001-04, Vol.219 (1), p.203

2001

Link zum Volltext

Verfügbarkeit prüfen

Beyond hydrogeologic evidence: challenging the current assumptions about salinity processes in the Corangamite region, Australia

Hydrogeology journal, 2008-11, Vol.16 (7), p.1283-1298

2008

Link zum Volltext

Verfügbarkeit prüfen

Concern About Falling Is Associated With Gait Speed, Independently From Physical and Cognitive Function

Physical therapy, 2019-08, Vol.99 (8), p.989-997

2019

Link zum Volltext

Verfügbarkeit prüfen

Radiation therapy for benign disease of the orbit

Seminars in radiation oncology, 1999-04, Vol.9 (2), p.179-189

1999

Link zum Volltext

Verfügbarkeit prüfen

Radiotherapy is successful treatment for orbital lymphoma

International journal of radiation oncology, biology, physics, 1993-04, Vol.26 (1), p.59-66

1993

Link zum Volltext

Verfügbarkeit prüfen

Utility of three-dimensional planning for axillary node coverage with breast-conserving radiation therapy: early experience

Radiology, 1999-01, Vol.210 (1), p.221

1999

Link zum Volltext

Verfügbarkeit prüfen

Is diagnostic review of radiotherapy-planning CT scans important in the conformal therapy era?

American journal of roentgenology (1976), 2001-09, Vol.177 (3), p.521

2001

Link zum Volltext

Verfügbarkeit prüfen

Breast-conserving radiation therapy: potential of inverse planning with intensity modulation

Radiology, 1997-06, Vol.203 (3), p.871

1997

Link zum Volltext

Verfügbarkeit prüfen

Abstract P4-21-26: Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P4-P4-21-26

2017

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

The lancet oncology, 2017-06, Vol.18 (6), p.743-754

2017

Link zum Volltext

Verfügbarkeit prüfen

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The lancet oncology, 2014-06, Vol.15 (7), p.689-699

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.S5-S5-05

2016

Link zum Volltext

Verfügbarkeit prüfen

Predictors of Discordance between Symptoms and Signs in Dry Eye Disease

Ophthalmology (Rochester, Minn.), 2017-03, Vol.124 (3), p.280-286

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.GS1-10-GS1-10

2019

Link zum Volltext

Verfügbarkeit prüfen

Fibreoptic intubation with and without Sellickʼs maneuver: 19AP1-2

European journal of anaesthesiology, 2012-06, Vol.29, p.227

2012

Link zum Volltext

Verfügbarkeit prüfen

Women's use of resources in decision-making for early-stage breast cancer: results of a community-based survey

Annals of surgical oncology, 1997-10, Vol.4 (7), p.564-569

1997

Link zum Volltext

Verfügbarkeit prüfen

8519 A phase 2, randomized trial (CONCERT-1) of chemoradiotherapy with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Interim pooled safety analysis

European journal of cancer supplements, 2009, Vol.7 (2), p.476-476

2009

Link zum Volltext

Verfügbarkeit prüfen

8516 A phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): interim pooled safety analysis

European journal of cancer supplements, 2009, Vol.7 (2), p.475-475

2009

Link zum Volltext

Verfügbarkeit prüfen

7110 Efficacy and safety of AMG 102 in patients with advanced renal cell carcinoma (RCC)

European journal of cancer supplements, 2009, Vol.7 (2), p.426-426

2009

Link zum Volltext

Verfügbarkeit prüfen

Association Between Severe Dental Caries and Child Abuse and Neglect

Journal of oral and maxillofacial surgery, 2017-11, Vol.75 (11), p.2304-2306

2017

Link zum Volltext

Verfügbarkeit prüfen

Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.OT1-1-06-OT1-1-06

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 349

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(312)
Mit Volltextzugriff
(299)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

The duration of fibre-optic intubation is increased by cricoid pressure. A randomised double-blind study

The importance of the lumpectomy surgical margin status in long term results of breast conservation

Breast electron boost planning: comparison of CT and US

Beyond hydrogeologic evidence: challenging the current assumptions about salinity processes in the Corangamite region, Australia

Concern About Falling Is Associated With Gait Speed, Independently From Physical and Cognitive Function

Radiation therapy for benign disease of the orbit

Radiotherapy is successful treatment for orbital lymphoma

Utility of three-dimensional planning for axillary node coverage with breast-conserving radiation therapy: early experience

Is diagnostic review of radiotherapy-planning CT scans important in the conformal therapy era?

Breast-conserving radiation therapy: potential of inverse planning with intensity modulation

Abstract P4-21-26: Population pharmacokinetics (PK) and exposure-response (E-R) analysis of trastuzumab emtansine (T-DM1) in patients with HER2+ metastatic breast cancer (MBC) who have received at least two prior regimens of HER2-directed therapy

Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

Abstract S5-05: Trastuzumab emtansine improves overall survival versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study

Predictors of Discordance between Symptoms and Signs in Dry Eye Disease

Abstract GS1-10: Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: Primary results from KATHERINE

Fibreoptic intubation with and without Sellickʼs maneuver: 19AP1-2

Women's use of resources in decision-making for early-stage breast cancer: results of a community-based survey

8519 A phase 2, randomized trial (CONCERT-1) of chemoradiotherapy with or without panitumumab in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): Interim pooled safety analysis

8516 A phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): interim pooled safety analysis

7110 Efficacy and safety of AMG 102 in patients with advanced renal cell carcinoma (RCC)

Association Between Severe Dental Caries and Child Abuse and Neglect

Abstract OT1-1-06: A phase 3, randomized, open-label trial comparing trastuzumab emtansine and trastuzumab as adjuvant therapy for HER2-positive primary breast cancer with residual invasive tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE)

Suchergebnisse filtern